Loading...

HCWB HCW BIOLOGICS INC Company Mergers 8-K Filing

HCW

HCWB

HCW BIOLOGICS INC

(HCWB)

2026 8-K

Nasdaq Compliance Update

License Termination

Equity Offering Report

Quarterly Financial Results

Adjourned Meeting

Consulting Agreements

Bylaw Amendment

Financial Results Release

License Agreement Closed

Regained Compliance

Securities Offering

Exclusive License Agreement

Regulatory Compliance Update

Investor Agreement Details

License Agreement Update

Clinical Trial Update

Financial Results Released

Nasdaq Compliance Update

Payment Extension Update

Delisting Notice

Filing Amendment Notice

Equity Purchase Amendment

Financial Results

Rights Offerings

Voluntary Delisting

Rights Offerings

Management Changes

Asset Acquisitions

Equity Offerings

Rights Offerings

Equity Offerings

Financial Statements

Equity Offerings

Equity Agreement

Stock Split Approval

Financial Results

Agreement Amendment

Nasdaq Delisting Notice

Equity Purchase Agreement

Nasdaq Delisting Notice

Nasdaq Delisting Notice

Securities Agreement

License Agreement

Financial Results

Financial Results

Nasdaq Compliance Notice

Settlement Agreement and Re...

Delisting Notice

Annual Meeting of Stockholders

Financial Results Announcement

Criminal Fraud Event

Financial Results Announcement

Agreement for Stock Sale

Termination of Credit Agree...

Financial Results Announcement

Financial Results Announcement

Annual Meeting Results

Financial Results Announcement

Agreement for Line of Credit

Financial Results Announcement

External Links:

On February 13, 2026, HCW Biologics Inc. announced a worldwide license agreement with WY Biotech Co., Ltd. for developing HCW11-006 and exclusive rights to clinical development in Greater China for HCW9302. This agreement aims to enhance their portfolio in autoimmune disorder treatments.

AI Assistant

HCW BIOLOGICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.